valproic acid and carbidopa

valproic acid has been researched along with carbidopa in 12 studies

Research

Studies (12)

TimeframeStudies, this research(%)All Research%
pre-19902 (16.67)18.7374
1990's1 (8.33)18.2507
2000's0 (0.00)29.6817
2010's9 (75.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Jones, LH; Nadanaciva, S; Rana, P; Will, Y1
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ1
Ekins, S; Williams, AJ; Xu, JJ1
Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC1
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V1
Calne, DB; Eng, N; Nutt, J; Plotkin, C; Williams, A; Ziegler, M1
Chung, EY; Rosenbaum, D; Van Woert, MH1
Onofrj, M; Paci, C; Thomas, A1
Foote, KD; Hassan, A; Iyer, S; McFarland, NR; Okun, MS; Rodriguez, RL; Sriram, A; Ward, HE1
Epstein, J; Hayes, MT; Lai, L; Madiedo, CJ1

Reviews

1 review(s) available for valproic acid and carbidopa

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Trials

1 trial(s) available for valproic acid and carbidopa

ArticleYear
Treatment of Parkinson's disease with sodium valproate: clinical, pharmacological, and biochemical observations.
    The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques, 1979, Volume: 6, Issue:3

    Topics: Aged; Carbidopa; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Female; gamma-Aminobutyric Acid; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Valproic Acid

1979

Other Studies

10 other study(ies) available for valproic acid and carbidopa

ArticleYear
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
    Drug metabolism and disposition: the biological fate of chemicals, 2012, Volume: 40, Issue:12

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship

2012
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
    Bioorganic & medicinal chemistry letters, 2016, 08-15, Volume: 26, Issue:16

    Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone

2016
Developing structure-activity relationships for the prediction of hepatotoxicity.
    Chemical research in toxicology, 2010, Jul-19, Volume: 23, Issue:7

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes

2010
A predictive ligand-based Bayesian model for human drug-induced liver injury.
    Drug metabolism and disposition: the biological fate of chemicals, 2010, Volume: 38, Issue:12

    Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands

2010
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
    Bioorganic & medicinal chemistry letters, 2010, Dec-15, Volume: 20, Issue:24

    Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility

2010
FDA-approved drug labeling for the study of drug-induced liver injury.
    Drug discovery today, 2011, Volume: 16, Issue:15-16

    Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration

2011
Biochemistry and therapeutics of posthypoxic myoclonus.
    Advances in neurology, 1986, Volume: 43

    Topics: 5-Hydroxytryptophan; Adrenocorticotropic Hormone; Aspartic Acid; Benzodiazepines; Carbidopa; Electroencephalography; gamma-Aminobutyric Acid; Glycine; Humans; Hydroxyindoleacetic Acid; Hypoxia; Methysergide; Models, Biological; Myoclonus; Prednisone; Serotonin; Tryptophan; Valproic Acid

1986
Reversible parkinsonism induced by prolonged treatment with valproate.
    Journal of neurology, 1998, Volume: 245, Issue:12

    Topics: Aged; Anticonvulsants; Antiparkinson Agents; Carbidopa; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease, Secondary; Remission Induction; Seizures; Valproic Acid

1998
Valproate as a treatment for dopamine dysregulation syndrome (DDS) in Parkinson's disease.
    Journal of neurology, 2013, Volume: 260, Issue:2

    Topics: Aged; Aged, 80 and over; Akathisia, Drug-Induced; Anticonvulsants; Carbidopa; Disruptive, Impulse Control, and Conduct Disorders; Dopamine Agents; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Valproic Acid

2013
Successful treatment of dopamine dysregulation syndrome with valproic acid.
    The Journal of neuropsychiatry and clinical neurosciences, 2014,Summer, Volume: 26, Issue:3

    Topics: Antimanic Agents; Carbidopa; Compulsive Behavior; Dopamine Agonists; Drug Combinations; Female; Humans; Levodopa; Middle Aged; Parkinson Disease; Valproic Acid

2014